mydanilo Posted - 8 hours ago

$amgn @ThatsMyFknScubaSuit IF, but let's hope. "The company is also testing tarlatamab for treating patients with earlier-stage small cell lung cancer. If those studies prove successful, Wall Street analysts have said tarlatamab could represent an annual sales opportunity for the company of more than $2 billion."

GemsBot Posted - 10 hours ago

1 of 11 $AAPL $AMGN $AMZN Daily and 30 min charts of the DJIA Components with the SSI indicator, a proprietary indicator based exclusively on the eSignal platform, are posted here weekends … see 2/11

bavariaron Posted - 1 day ago

$VKTX — Storm the Castle —- ** 4 Stocks: Duopoly Busters? ** https://finance.yahoo.com/news/4-stocks-could-break-novo-140400901.html $ALT $AMGN $VKTX $RHHBY

ThatsMyFknScubaSuit Posted - 1 day ago

$AMGN $LLY What did everyone gossip about at the Met Gala this year? Weight loss treatments

ThatsMyFknScubaSuit Posted - 1 day ago

$AMGN $SPY The approval of their Small Cell Lung Cancer treatment cost 780,000 and is projected to generate 2 billion in additional annual sales Representing a 6% revenue growth for the fiscal year

Stoxpo Posted - 1 day ago

Breaking: 📢📢📢📢 Amgen’s $AMGN Imdelltra Receives @US_FDA Approval as Breakthrough Lung Cancer Treatment https://stoxpo.com/index.php/2024/05/17/amgens-imdelltra-receives-fda-approval-as-breakthrough-lung-cancer-treatment/ $AMGN $QQQ @Amgen @US_FDA

ThatsMyFknScubaSuit Posted - 1 day ago

$AMGN still adding. Probably a mistake

ThatsMyFknScubaSuit Posted - 1 day ago

$AMGN of course it was another sell the news event Sigh

DefenseMania Posted - 1 day ago

Keep an eye on these presentations 😉 $GILD $AMGN $AZN $PFE https://finance.yahoo.com/news/arcus-biosciences-present-data-phase-200000387.html

impact80 Posted - 1 day ago

$AMGN Pump and dump stock

MoneyForFun_ Posted - 1 day ago

$AMGN and $NVAX ✅

DonCorleone77 Posted - 2 days ago

$AMGN Amgen says FDA approves Imdelltra Amgen announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). "The FDA's approval of IMDELLTRA marks a pivotal moment for patients battling ES-SCLC. This DLL3-targeting therapy in ES-SCLC comprises a transformative option demonstrating long-lasting responses in pretreated patients," said Jay Bradner, M.D., executive vice president, Research and Development, and chief scientific officer at Amgen. "This approval further demonstrates our commitment to addressing aggressive cancers through our second FDA-approved Bispecific T-cell Engager (BiTE) molecule. IMDELLTRA offers these patients who are in urgent need of new innovative therapies hope, and we're proud to deliver this long-awaited effective treatment to them."

LeLionEtLeRat Posted - 2 days ago

$VKTX while I have a lot of respect for the company’s leadership and their achievements, the effect of $AMGN and Roche successive data release might be a useful reality check. The TAM is huge but the competition is fierce. Perhaps it’s time to show more openness and flexibility on BO or partnership. Imo VKTX won’t be able to succeed on its own. The last couple of weeks might be a blessing in disguise. https://www.biopharmadive.com/news/roche-obesity-drug-phase-1-data-carmot-glp1-gip/716308/

Stock_Titan Posted - 2 days ago

$AMGN FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER https://www.stocktitan.net/news/AMGN/fda-approves-imdelltra-tarlatamab-dlle-the-first-and-only-t-cell-dz6ae7mfpr8q.html

DonCorleone77 Posted - 2 days ago

$AMGN FDA grants accelerated approval for Amgen's tarlatamab-dlle The Food and Drug Administration granted accelerated approval to tarlatamab-dlle, or Imdelltra, from Amgen for extensive stage small cell lung cancer, or ES-SCLC, with disease progression on or after platinum-based chemotherapy.

Ro_Patel Posted - 2 days ago

Yet again, news driven algos hit $LLY after headlines like: Roche's New Weight-Loss Data Shows Lilly Isn't Unbeatable in Obesity -- Barrons Dig deeper..... Roche CT-388 is currently only in a Phase 1b trial involving 96 people but only 31 trial participants considered overall. Roche is awaiting additional data from a study of the drug & didn’t provide specifics on the drug’s side effect profile. except saying CT-388 was well tolerated with “mild to moderate gastrointestinal-related adverse events being the most common, consistent with the incretin class of medicines that CT-388 belongs to.” The drug is a dual GLP-1/GIP receptor agonist - similar to Mounjaro & Zepbound - this drug doesn't really raise the bar IMHO CT-388 & other obesity drugs from $AMGN $ALT $VKTX $PFE etc still have years before getting FDA approval &/or having adequate manufacturing/supply.

Cathwoodie Posted - 2 days ago

$AMGN $325 gaining momentum - big move tonight to tomorrow

TradeHawk Posted - 2 days ago

$AMGN Amgen gets FDA approval of Imdelltra for the treatment of adult patients with advanced small cell lung cancer. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf

Phil7777777777 Posted - 2 days ago

$VKTX $NVO $AMGN $RHHBY

Power2k Posted - 2 days ago

$VKTX First $NVO, then $AMGN, and now $RHHBY, every time a big name releases early obesity trial data (even incomplete or questionable), we got hammered. Nevertheless, VK2735 is still the best-in-class GLP/GIP dual agonist. Ain't selling, and Holding thru BO or final approval.

Mitz007 Posted - 2 days ago

$AMGN $HUMA -$Amgn may be heading na ask to consolidation post Glp 1 before another move up . Targets were given look for 300 and below in coming days

SportsBetz Posted - 2 days ago

$HUMA Or - buy a little now for cheaper then the former CEO of $AMGN Gordon Binder did when he bought a 100,000 shares at 6.75 yesterday. Save room to add lower. But current prices cheaper than a 100,000 share block. Not rocket science.

DefenseMania Posted - 2 days ago

$ABBV fueling like a big biotech merger is brewing $AZN + $GILD ? $AMGN $PFE

kshonstocks Posted - 2 days ago

ex $amgn ceo insider buy $HUMA https://www.sec.gov/Archives/edgar/data/1291957/000181838224000058/xslF345X05/wk-form4_1715815434.xml and size too a good sign

yekoiob Posted - 3 days ago

$HUMA The ex-CEO of $AMGN is on the board of $HUMA and is buying 100k shares at $6.57 to $6.78, I'll take that over Tuberville any day

RedBear Posted - 3 days ago

$AMGN breakout still intact

Mitz007 Posted - 3 days ago

$AMGN went past 321 322 was my upper level on this ..

Mitz007 Posted - 3 days ago

$AMGN on track .. stay tuned .

Mitz007 Posted - 3 days ago

$AMGN knew this was coming …

DefenseMania Posted - 3 days ago

$RCUS 1hr before healthcare conference $PFE $GILD $AMGN $ABBV